| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 517 | 2022 |
| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 377 | 2021 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 210 | 2021 |
| Prevalence of depression in students of a medical college in New Delhi: a cross-sectional study S Sidana, J Kishore, V Ghosh, D Gulati, RC Jiloha, T Anand The Australasian medical journal 5 (5), 247, 2012 | 204 | 2012 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England Journal of Medicine 389 (4), 335-347, 2023 | 195 | 2023 |
| Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer RJ Molenaar, S Sidana, T Radivoyevitch, AS Advani, AT Gerds, ... Journal of clinical oncology 36 (18), 1831-1839, 2018 | 139 | 2018 |
| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 131 | 2023 |
| Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results S Mailankody, JV Matous, S Chhabra, M Liedtke, S Sidana, OO Oluwole, ... Nature medicine 29 (2), 422-429, 2023 | 120 | 2023 |
| Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma JH Baird, DJ Epstein, JS Tamaresis, Z Ehlinger, JY Spiegel, J Craig, ... Blood advances 5 (1), 143-155, 2021 | 119 | 2021 |
| Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia S Sidana, SV Rajkumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, ... American journal of hematology 92 (7), 668-673, 2017 | 101 | 2017 |
| International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ... Leukemia 35 (1), 18-30, 2021 | 94 | 2021 |
| Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma S Mailankody, JV Matous, M Liedtke, S Sidana, S Malik, R Nath, ... Blood 136, 24-25, 2020 | 75 | 2020 |
| Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities R Chakraborty, S Sidana, GL Shah, M Scordo, BK Hamilton, NS Majhail Biology of Blood and Marrow Transplantation 25 (5), e155-e162, 2019 | 74 | 2019 |
| CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma JH Baird, MJ Frank, J Craig, S Patel, JY Spiegel, B Sahaf, JS Oak, ... Blood, The Journal of the American Society of Hematology 137 (17), 2321-2325, 2021 | 68 | 2021 |
| Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ... Leukemia 32 (3), 729-735, 2018 | 54 | 2018 |
| Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer S Chaturvedi, S Sidana, P Elson, AA Khorana, KR McCrae PLoS One 9 (8), e94048, 2014 | 53 | 2014 |
| IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features S Sidana, DP Larson, PT Greipp, R He, ED McPhail, A Dispenzieri, ... Leukemia 34 (5), 1373-1382, 2020 | 52 | 2020 |
| Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis S Sidana, MH Sidiqi, A Dispenzieri, FK Buadi, MQ Lacy, E Muchtar, ... American journal of hematology 94 (9), 1020-1026, 2019 | 52 | 2019 |
| Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma JM Logue, LC Peres, H Hashmi, CM Colin-Leitzinger, AM Shrewsbury, ... Blood Advances 6 (24), 6109-6119, 2022 | 49 | 2022 |
| Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma P Moreau, SZ Usmani, AL Garfall, NWCJ van de Donk, H Nahi, ... Blood 138, 896, 2021 | 49 | 2021 |
